<?xml version='1.0' encoding='utf-8'?>
<document id="22359337"><sentence text="New cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GC-MS and LC-high-resolution MS and their detectability in urine."><entity charOffset="4-13" id="DDI-PubMed.22359337.s1.e0" text="cathinone" /><entity charOffset="37-57" id="DDI-PubMed.22359337.s1.e1" text="3-bromomethcathinone" /><entity charOffset="62-83" id="DDI-PubMed.22359337.s1.e2" text="3-fluoromethcathinone" /><pair ddi="false" e1="DDI-PubMed.22359337.s1.e0" e2="DDI-PubMed.22359337.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22359337.s1.e0" e2="DDI-PubMed.22359337.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22359337.s1.e0" e2="DDI-PubMed.22359337.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22359337.s1.e1" e2="DDI-PubMed.22359337.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22359337.s1.e1" e2="DDI-PubMed.22359337.s1.e2" /></sentence><sentence text="3-Bromomethcathinone (3-BMC) and 3-Fluoromethcathinone (3-FMC) are two new designer drugs, which were seized in Israel during 2009 and had also appeared on the illicit drug market in Germany"><entity charOffset="0-20" id="DDI-PubMed.22359337.s2.e0" text="3-Bromomethcathinone" /><entity charOffset="22-27" id="DDI-PubMed.22359337.s2.e1" text="3-BMC" /><entity charOffset="33-54" id="DDI-PubMed.22359337.s2.e2" text="3-Fluoromethcathinone" /><entity charOffset="56-61" id="DDI-PubMed.22359337.s2.e3" text="3-FMC" /><pair ddi="false" e1="DDI-PubMed.22359337.s2.e0" e2="DDI-PubMed.22359337.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22359337.s2.e0" e2="DDI-PubMed.22359337.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22359337.s2.e0" e2="DDI-PubMed.22359337.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22359337.s2.e0" e2="DDI-PubMed.22359337.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22359337.s2.e1" e2="DDI-PubMed.22359337.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22359337.s2.e1" e2="DDI-PubMed.22359337.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22359337.s2.e1" e2="DDI-PubMed.22359337.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22359337.s2.e2" e2="DDI-PubMed.22359337.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22359337.s2.e2" e2="DDI-PubMed.22359337.s2.e3" /></sentence><sentence text=" These two compounds were sold via the Internet as so-called &quot;bath salts&quot; or &quot;plant feeders" /><sentence text="&quot; The aim of the present study was to identify for the first time the 3-BMC and 3-FMC Phase I and II metabolites in rat urine and human liver microsomes using GC-MS and LC-high-resolution MS (HR-MS) and to test for their detectability by established urine screening approaches using GC-MS or LC-MS"><entity charOffset="70-75" id="DDI-PubMed.22359337.s4.e0" text="3-BMC" /><entity charOffset="283-288" id="DDI-PubMed.22359337.s4.e1" text="GC-MS" /><entity charOffset="80-84" id="DDI-PubMed.22359337.s4.e2" text="3-FMC" /><entity charOffset="159-163" id="DDI-PubMed.22359337.s4.e3" text="GC-MS" /><pair ddi="false" e1="DDI-PubMed.22359337.s4.e0" e2="DDI-PubMed.22359337.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22359337.s4.e0" e2="DDI-PubMed.22359337.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22359337.s4.e0" e2="DDI-PubMed.22359337.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22359337.s4.e0" e2="DDI-PubMed.22359337.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22359337.s4.e2" e2="DDI-PubMed.22359337.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22359337.s4.e2" e2="DDI-PubMed.22359337.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22359337.s4.e2" e2="DDI-PubMed.22359337.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22359337.s4.e3" e2="DDI-PubMed.22359337.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22359337.s4.e3" e2="DDI-PubMed.22359337.s4.e1" /></sentence><sentence text=" Furthermore, the human cytochrome-P450 (CYP) isoenzymes responsible for the main metabolic steps were studied to highlight possible risks of consumption due to drug-drug interaction or genetic variations" /><sentence text=" For the first aim, rat urine samples were extracted after and without enzymatic cleavage of conjugates" /><sentence text=" The metabolites were separated and identified by GC-MS and by LC-HR-MS"><entity charOffset="50-54" id="DDI-PubMed.22359337.s7.e0" text="GC-MS" /></sentence><sentence text=" The main metabolic steps were N-demethylation, reduction of the keto group to the corresponding alcohol, hydroxylation of the aromatic system and combinations of these steps"><entity charOffset="97-104" id="DDI-PubMed.22359337.s8.e0" text="alcohol" /><entity charOffset="127-135" id="DDI-PubMed.22359337.s8.e1" text="aromatic" /><pair ddi="false" e1="DDI-PubMed.22359337.s8.e0" e2="DDI-PubMed.22359337.s8.e0" /><pair ddi="false" e1="DDI-PubMed.22359337.s8.e0" e2="DDI-PubMed.22359337.s8.e1" /></sentence><sentence text=" The elemental composition of the metabolites identified by GC-MS could be confirmed by LC-HR-MS"><entity charOffset="60-67" id="DDI-PubMed.22359337.s9.e0" text="GC-MS" /></sentence><sentence text=" Furthermore, corresponding Phase II metabolites were identified using the LC-HR-MS approach" /><sentence text=" For both compounds, detection in rat urine was possible within the authors' systematic toxicological analysis using both GC-MS and LC-MS(n) after a suspected recreational users dose"><entity charOffset="122-126" id="DDI-PubMed.22359337.s11.e0" text="GC-MS" /></sentence><sentence text=" Following CYP enzyme kinetic studies, CYP2B6 was the most relevant enzyme for both the N-demethylation of 3-BMC and 3-FMC after in vitro-in vivo extrapolation"><entity charOffset="107-111" id="DDI-PubMed.22359337.s12.e0" text="3-BMC" /><entity charOffset="117-121" id="DDI-PubMed.22359337.s12.e1" text="3-FMC" /><pair ddi="false" e1="DDI-PubMed.22359337.s12.e0" e2="DDI-PubMed.22359337.s12.e0" /><pair ddi="false" e1="DDI-PubMed.22359337.s12.e0" e2="DDI-PubMed.22359337.s12.e1" /></sentence><sentence text="" /></document>